Satiogen Pharmaceuticals has discovered a metabolic mechanism of action – termed "the bile acid brake" – that is a novel target for treating type 2 diabetes and obesity without intervention by systemically absorbed drugs or invasive surgical methods. Preclinical experiments testing several drugable concepts have demonstrated metabolic effects comparable to marketed drugs, and a clinical study has extended these findings to humans. Preclinical experiments are also underway with a non-surgical device designed to replicate the benefits of gastric bypass surgery.